InMode confirmed receipt of an unsolicited takeover proposal from a CEO group at $16.20 per share. The bid values the company and reflects ongoing consolidation interest in the energy-device space, where margin-rich RF, ultrasound, and combination platforms command premium multiples.
Business & M&A
InMode Receives Unsolicited Buyout Proposal at $16.20 per Share — M&A Signals Consolidation Pressure
CEO-led group bids for InMode; signals continued PE and strategic interest in energy-device consolidation.
CEO-led group bids $16.20 per share; signals continued PE interest in energy-device consolidation.
InMode manufactures the BodyTite, FaceTite, and Morpheus8 platforms—workhorse RF and microneedling devices widely deployed in U.S. practices. A successful acquisition could trigger changes to pricing, rebate structures, service agreements, or product roadmap prioritization under new ownership. For practices, M&A activity in the device tier signals potential margin compression as acquirers seek synergies and operational leverage. Monitor the outcome and any post-close announcements regarding service, support, or pricing terms.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.